TY  - BOOK
AU  - Cornes,Paul
AU  - McBride,Ali
TI  - Biosimilars in hematology and oncology
T2  - Fast facts
SN  - 9781912776221 (PDF ebook) :
PY  - 2020///
CY  - Abingdon, Oxford
PB  - Karger
KW  - Pharmaceutical biotechnology
KW  - Hematology
KW  - Oncology
KW  - Technology, Pharmaceutical
KW  - Medical Oncology
N1  - Also issued in print: 2020; Includes bibliographical references and index; Specialized
N2  - Biologics have revolutionised - and are revolutionising - the treatment of many serious disorders. The evidence acquired from more than 10 years of clinical experience, with more than 50 biosimilar drugs and more than 700 million patient-days' exposure in Europe, shows that approved biosimilars can be used as safely and effectively as originator biologics. Yet concerns persist about biosimilars - particularly in curative cancer treatment, where they are relatively recent therapeutic options. 'Biosimilars in Hematology and Oncology' provides a concise overview of emerging global practice in this fast-moving area together with practical information on adding biosimilars to a formulary and switching patients
UR  - #gotoholdings
ER  -